Palvella Therapeutics (PVLA) Current Deferred Revenue (2013 - 2023)

Palvella Therapeutics (PVLA) has 9 years of Current Deferred Revenue data on file, last reported at $3.5 million in Q3 2023.

• On a quarterly basis, Current Deferred Revenue rose 400.0% year-over-year to $3.5 million in Q3 2023; TTM through Sep 2023 was $3.5 million, a 400.0% increase from a year earlier, with the FY2022 full-year figure at $20.8 million, down 17.09% from the prior year.
• Current Deferred Revenue for Q3 2023 stood at $3.5 million, down from $4.7 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for PVLA reached as high as $28.4 million in Q2 2019 and fell as low as $700000.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $17.4 million across 5 years, with a median of $20.8 million in 2022.
• Across the five-year window, Current Deferred Revenue slumped 97.35% in 2022 and soared 400.0% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $11.3 million in 2019, then rose by 12.18% to $12.6 million in 2020, then jumped by 98.91% to $25.1 million in 2021, then retreated by 17.09% to $20.8 million in 2022, then sank by 83.19% to $3.5 million in 2023.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $3.5 million in Q3 2023, $4.7 million in Q2 2023, and $26.7 million in Q1 2023.